Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT06582264 is registered in ClinicalTrials.gov with Microbiotica Ltd as lead sponsor.

NCT NCT06582264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06582264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
Lead sponsor
Microbiotica Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2024
Completion date
January 8, 2026
Enrollment
29 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis